The UK government will end Palantir’s contract to run the National Health Service’s federated data platform in England in March 2029, health minister James Frith told the House of Commons on Monday, November 16, 2026. Ministers decided not to use a break clause that falls due early next year. They will run a new competition instead, built to bring in more suppliers.
For Palantir’s shareholders the money is small. The contract was worth up to £330 million over seven years when it was awarded, which is about £47 million a year, and Palantir shares it with four partner firms. At Tuesday’s exchange rate that is $62 million a year, or 0.7% of Palantir’s current annual revenue, TECHi’s calculation shows. The stock fell 4.5% on Monday and was down about 3% more late on Tuesday morning.
Article Brief
Key Takeaways
4 Points24s Read
- The decisionPalantir’s NHS data platform contract in England will run two more years and end in March 2029. A new competition starts in January.
- The sizeThe contract ceiling was £330 million over seven years, about $62 million a year. That is 0.7% of Palantir’s current annual revenue.
- The weak spotRevenue outside the United States grew 26% last quarter, against 119% at home, and is now 16% of the total.
- The pricePalantir trades at 81 times next year’s expected earnings. Monday’s fall erased $18 billion of market value.
What did the UK decide?
The contract covers the federated data platform, software that connects information NHS hospitals already hold, such as waiting lists, operating theatre schedules and discharge plans. Frith described it as software that fetches data for the person who needs it and then returns it to where it is kept, so there is no single central store. He said it is live in 142 hospital trusts and 35 regional care boards.
Those numbers were disputed in the chamber. Frith said 170 trusts have signed up, 142 have switched the platform on and 137 are seeing benefits. One MP put the number really using it at 108, noting that NHS England had recently withdrawn the 137 figure after 29 trusts said they were not live.
He announced three things. The NHS will start a new procurement for the next version of the platform, with talks with the market from January and a formal tender in the second half of 2027. The whole process should take about 18 months. Eighteen months from January runs to the middle of 2028, which would leave under a year for the switch. Until then the current contract stays in place for two more years, and then it ends.
Frith called the extension “a bridge, not the destination.” He gave the reasons as less dependence on any single supplier, more use of what the government calls sovereign AI, and common data standards so that different vendors’ products can work together. He pointed to Friday’s worldwide outage of Microsoft systems as a reminder of what over-dependence costs, and noted that the Budget set aside a further £140 million for sovereign AI.
Several members of Parliament had wanted the break clause used in February 2027 and criticised the two-year extension. Frith said his judgment was based on the platform’s performance for patients, not on the supplier or the politics of its executives. He also said Palantir had written to him that the exit terms are clear and that the NHS has the rights and support it needs to move to a new supplier.
One point has been lost in some headlines. Palantir is not barred from the next round. Frith said the new process would be open to suppliers from the UK and abroad, while offering new prospects for UK-based companies.
How big is the contract for Palantir?
The NHS announced the award in November 2023. It went to a group led by Palantir Technologies UK, working with Accenture, PwC, NECS and Carnall Farrar. Spending was expected to be at least £25.6 million in the first year and up to £330 million over the full term of seven years.
Those are ceilings, and they cover the whole group. Palantir’s own share has not been published. Even so, the ceiling is enough to size the risk.
Palantir reported revenue of $2.31 billion for the three months to September 30, up 96% from a year earlier. That is a pace of $9.25 billion a year, or about $25 million a day. Against that, the average annual value of the NHS contract, $62 million, is 0.7%. The entire seven-year ceiling, $435 million, is about 17 days of revenue.
What Palantir actually loses is smaller again. Ending in March 2029 cuts the seven-year maximum short by up to two years. At the average rate that is about £94 million, or $124 million, which is roughly five days of revenue at the current pace. Palantir’s filing also says no single customer accounted for more than 10% of revenue in the quarter.
Government work is no longer the larger half of the business either. Commercial customers brought in $1.17 billion in the quarter, up 113%, slightly more than the $1.15 billion from governments, which was up 81%.
| Measure | In pounds | In dollars | Against Palantir’s revenue |
|---|---|---|---|
| Contract ceiling over seven years | £330M | $435M | About 17 days of revenue |
| Average per year | £47M | $62M | 0.7% of annual revenue |
| Up to two years not delivered | £94M | $124M | About five days of revenue |
| First contract year, minimum | £25.6M | $34M | 0.4% of annual revenue |
Why does the stock care?
The answer is in a different line of the same filing. Palantir’s growth is almost entirely American.
Revenue from customers in the United States rose 119% in the third quarter, to $1.94 billion. Revenue from the rest of the world rose 26%, to $376 million. The rest of the world is now 16% of the total, down from 25% a year earlier, and no country other than the United States reaches 10%.
The NHS decision touches that weak spot. The value at risk is small, but the reasoning is portable. A government decided that depending on one foreign supplier for core public data was a problem in itself, and built its next purchase around local firms and open standards. Other governments can make the same argument. TECHi looked at that risk in October, in a report on Palantir and sovereign AI.
Valuation is why a small contract can move the price. Palantir closed on Monday at $160.39, which is 81 times the $1.98 a share that analysts expect it to earn in 2027, according to estimates compiled by Nasdaq. At that price the company is worth about $386 billion. Monday’s fall alone erased $18 billion of value, 42 times the full seven-year ceiling of the NHS contract.
Most of that fall has other causes. AI stocks have been sold broadly for a week, and Nvidia’s troubles have set the tone, as TECHi’s report on Nvidia’s new oversight committee shows. Palantir is down 9.8% for the year at Monday’s close and 23% below its record close of $209.05 on October 9.
The case for shrugging it off
Palantir kept the contract for two years longer than its critics in Parliament wanted. It can bid for the next one. Frith also told MPs that hospitals should keep using the platform in the meantime, including those that have not yet signed up. The United States is where its growth is coming from, and the UK is too small a share of revenue to be reported on its own line.
The case against is about direction. Overseas revenue is growing at a fifth of the American rate. A stock priced at 81 times next year’s expected earnings needs every market to work, and a public decision to move away from the company, taken by an ally and explained in terms any government could borrow, is the opposite of that.
What to watch
The NHS begins talks with suppliers in January, and Frith promised more detail on new work in maternity care within weeks. The break clause date in February 2027 will now pass unused. Palantir’s next quarterly report, expected in February, will show whether revenue outside the United States is still growing at a fifth of the pace at home. TECHi’s Palantir quote page carries the live price.
